GZMK and neoplasm: Overall, GZMB+ cells comprised the majority (~50%) of circulating CD4+ cells with tumor-matched TCRs, and GZMB+ and GZMK+ cells together represented more than 40% of intratumoral CD4+ cells with blood-matched TCRs despite these cells constituting the minority of total CD4+ cells (Figure 2A).